[
    [
        {
            "time": "2018-03-05",
            "original_text": "Supreme Court Rebuffs Novartis Appeal Over Amgen's Arthritis Drug Enbrel: Report",
            "features": {
                "keywords": [
                    "Supreme Court",
                    "Novartis",
                    "Amgen",
                    "Arthritis",
                    "Drug",
                    "Enbrel"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-06",
            "original_text": "Novartis' Entresto Misses Primary Endpoint In Study After Heart Attacks",
            "features": {
                "keywords": [
                    "Novartis",
                    "Entresto",
                    "Primary Endpoint",
                    "Study",
                    "Heart Attacks"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-03-07",
            "original_text": "US Supreme Court denies Sandoz petition to review biosimilar ErelziÂ® (etanercept-szzs) case",
            "features": {
                "keywords": [
                    "US Supreme Court",
                    "Sandoz",
                    "petition",
                    "biosimilar",
                    "Erelzi",
                    "case"
                ],
                "sentiment_score": -0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-08",
            "original_text": "UPDATE 2-U.S. Supreme Court snubs Novartis appeal over arthritis drug Enbrel",
            "features": {
                "keywords": [
                    "U.S. Supreme Court",
                    "Novartis",
                    "arthritis",
                    "drug",
                    "Enbrel"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-03-09",
            "original_text": "U.S. Supreme Court snubs Novartis appeal over arthritis drug Enbrel",
            "features": {
                "keywords": [
                    "U.S. Supreme Court",
                    "Novartis",
                    "arthritis",
                    "drug",
                    "Enbrel"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]